Litcius/Paper detail

COVID-19 Vaccine and Hyperosmolar Hyperglycemic State

Mohammed Abu‐Rumaileh, Ahmad Gharaibeh, Naser Eddin Gharaibeh

2021Cureus43 citationsDOIOpen Access PDF

Abstract

Coronavirus disease 2019 (COVID-19) is a multi-system disease that causes multiple complications. It is linked to the development of new-onset diabetes or unmasking of underlying diabetes. Despite the uncertain exact mechanism, pancreatic angiotensin-converting enzyme 2 (ACE2) receptor, the main enzyme related to COVID-19 pathophysiology has been implied. COVID-19 vaccine was authorized to help control the rapid spread of COVID-19 disease. We report a case of new-onset diabetes type 2 presenting as hyperosmolar hyperglycemic state (HHS) in a patient after receiving COVID-19 vaccine with some literature review of the potential mechanisms by which COVID-19 may cause new-onset diabetes type 2.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Diabetes mellitusDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PathophysiologyCoronavirusType 2 diabetes2019-20 coronavirus outbreakAngiotensin-converting enzyme 2Internal medicineIntensive care medicineVirologyImmunologyEndocrinologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesDiabetes and associated disordersSARS-CoV-2 and COVID-19 Research
COVID-19 Vaccine and Hyperosmolar Hyperglycemic State | Litcius